An EIF1AX A113_splice site mutation in tandem with a RAS and/or TP53 mutation is associated with aggressive malignancies that have an inherent potential to progress toward poorly differentiated thyroid carcinoma. This evidence concerns the gene TP53 and thyroid gland carcinoma.